Naltrexone

CHEMBL19019 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

341.4 g/mol

LogP

1.9

Phase

4

This medication is used to help people who have stopped using opioids or alcohol from returning to these substances by blocking the pleasurable effects they would normally produce. It is taken daily as a tablet or given monthly as an injectable and works best as part of a comprehensive addiction treatment program.

Masse moléculaire

341,4000 g/mol

LogP

1,90

TPSA

70,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Endometriosis Cardiovascular Disease Respiratory Disease Pain Management Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Migraine Schizophrenia Bipolar Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain HIV/AIDS Tuberculosis Heart Failure Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5

InChI

InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1

Molecular Formula

C20H23NO4

HBD / HBA

2 / 5

Liaisons Rotatives

2

Atomes Lourds

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This medication is used to help people who have stopped using opioids or alcohol from returning to these substances by blocking the pleasurable effects they would normally produce. It is taken daily as a tablet or given monthly as an injectable and works best as part of a comprehensive addiction treatment program.

Yes, Naltrexone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL19019. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5360515. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Naltrexone sur PillFYI

Structure

Données Clés

Formule: C20H23NO4
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.